Ray Dalio’s Halozyme Therapeutics Inc (HALO) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Bridgewater Associates, LP first reported Halozyme Therapeutics Inc in Q2 2023. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 463.15K shares. The latest verified filing showed: Sold 9.4% of the position.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $78.27 · Estimated holding basis $72.54
Filing context
Quarter-end price $64.63 · Estimated holding basis $72.54
Filing context
Quarter-end price $67.30 · Estimated holding basis $72.54
Filing context
Quarter-end price $73.34 · Estimated holding basis $73.34
Filing context
Quarter-end price $57.24 · Estimated holding basis $48.90
Filing context
Quarter-end price $52.36 · Estimated holding basis $48.90
Filing context
Quarter-end price $40.68 · Estimated holding basis $36.07
Filing context
Quarter-end price $36.96 · Estimated holding basis $36.07
Filing context
Quarter-end price $38.20 · Estimated holding basis $36.07
Filing context
Quarter-end price $36.07 · Estimated holding basis $36.07
2 unchanged quarters are collapsed by default.
How important is Halozyme Therapeutics Inc in Bridgewater Associates, LP’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
Who else owns Halozyme Therapeutics Inc?
Also reported by 1 other tracked investor in their latest verified filings.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Market context only; not an investor transaction price.
Derived from validated reported value and shares where supported.
Calculated from supported filing history.
This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.